Importantly, dedicated heart failure trials [7–9] demonstrated the efficacy of SGLT2 inhibitors in individuals who had heart failure with reduced ejection fraction (HFrEF), with and without type 2 diabetes, suggesting that the salutary effects of these agents are not confined to diabetic conditions. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.